​

Gossamer Bio (GOSS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GOSS Stock Forecast

Gossamer Bio (GOSS) stock forecast, based on 17 Wall Street analysts, predicts a 12-month average price target of $0.77, with a high of $1.00 and a low of $0.30. This represents a 67.39% increase from the last price of $0.46.

High: $1 Avg: $0.77 Low: $0.3 Last Closed Price: $0.46

GOSS Stock Rating

Gossamer Bio stock's rating consensus is Buy, based on 17 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (58.82%), 5 Hold (29.41%), 2 Sell (11.76%), and 0 Strong Sell (0.00%).

Buy
Total 17 0 2 5 10 Strong Sell Sell Hold Buy Strong Buy

GOSS Price Target Upside V Benchmarks

TypeNameUpside
StockGossamer Bio67.39%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts345
Avg Price Target$0.77$2.83$4.06
Last Closing Price$0.46$0.46$0.46
Upside/Downside67.39%515.22%782.61%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26134-19
Feb, 26261--9
Jan, 26161--8
Dec, 25161--8
Nov, 25251--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 24, 2026Wedbush$1.00$0.42138.10%117.39%
Feb 24, 2026Eliana MerleBarclays$0.30$0.42-28.57%-34.78%
Feb 24, 2026Leerink Partners$1.00$0.42138.10%117.39%
Jan 27, 2026Barclays$9.00$2.64240.91%1856.52%
Sep 10, 2025UBS$9.00$3.11189.39%1856.52%
Dec 08, 2022H.C. Wainwright$5.00$2.16131.48%986.96%
Dec 07, 2022Barclays$2.00$2.36-15.25%334.78%
Dec 07, 2022Raymond James$5.00$2.36111.86%986.96%
Dec 06, 2022David HoangSMBC Nikko$3.00$2.3627.12%552.17%
Apr 26, 2022Barclays$12.00$8.4542.01%2508.70%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Feb 24, 2026WedbushNeutraldowngrade
Feb 24, 2026BarclaysOverweightUnderweightdowngrade
Feb 24, 2026RBC CapitalOutperformupgrade
Feb 24, 2026Leerink PartnersMarket Performdowngrade
Jan 27, 2026BarclaysEqual-WeightOverweightinitialise
Sep 10, 2025UBSBuyBuyupgrade
Jul 14, 2025ScotiabankOutperforminitialise
Sep 18, 2024H.C. WainwrightBuyBuyhold
Sep 12, 2024Piper SandlerOverweightOverweighthold
Jun 24, 2024OppenheimerBuyOutperforminitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.18$-0.25----
Avg Forecast$-1.24$-0.28$-0.71$-0.47$-0.19$0.09
High Forecast$-1.10$-0.18$-0.53$-0.14$0.35$0.17
Low Forecast$-1.36$-0.32$-0.96$-0.81$-0.62$0.04
Surprise %-4.84%-10.71%----

Revenue Forecast

$0 $70M $140M $210M $280M $350M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported-$114.70M----
Avg Forecast-$112.15M$21.07M$53.76M$105.88M$201.21M
High Forecast-$126.23M$35.71M$54.30M$105.88M$341.02M
Low Forecast-$105.85M$12.96M$53.22M$105.88M$123.74M
Surprise %-2.28%----

Net Income Forecast

$-250M $-180M $-110M $-40M $30M $100M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-179.82M$-56.53M----
Avg Forecast$-179.82M$-38.50M$-113.78M$-71.94M$-59.91M$13.74M
High Forecast$-167.36M$-27.72M$-80.50M$-20.80M$53.42M$26.14M
Low Forecast$-207.71M$-49.28M$-147.06M$-123.07M$-94.63M$6.86M
Surprise %-46.84%----

GOSS Forecast FAQ

Is Gossamer Bio stock a buy?

Gossamer Bio stock has a consensus rating of Buy, based on 17 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 5 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Gossamer Bio is a favorable investment for most analysts.

What is Gossamer Bio's price target?

Gossamer Bio's price target, set by 17 Wall Street analysts, averages $0.77 over the next 12 months. The price target range spans from $0.3 at the low end to $1 at the high end, suggesting a potential 67.39% change from the previous closing price of $0.46.

How does Gossamer Bio stock forecast compare to its benchmarks?

Gossamer Bio's stock forecast shows a 67.39% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Gossamer Bio over the past three months?

  • March 2026: 11.11% Strong Buy, 33.33% Buy, 44.44% Hold, 0% Sell, 11.11% Strong Sell.
  • February 2026: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 12.50% Strong Buy, 75.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Gossamer Bio’s EPS forecast?

Gossamer Bio's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.71, marking a 184.00% increase from the reported $-0.25 in 2024. Estimates for the following years are $-0.47 in 2026, $-0.19 in 2027, and $0.09 in 2028.

What is Gossamer Bio’s revenue forecast?

Gossamer Bio's average annual revenue forecast for its fiscal year ending in December 2025 is $21.07M, reflecting a -81.63% decrease from the reported $114.7M in 2024. The forecast for 2026 is $53.76M, followed by $105.88M for 2027, and $201.21M for 2028.

What is Gossamer Bio’s net income forecast?

Gossamer Bio's net income forecast for the fiscal year ending in December 2025 stands at $-114M, representing an 101.28% increase from the reported $-56.528M in 2024. Projections indicate $-71.937M in 2026, $-59.909M in 2027, and $13.74M in 2028.